BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 20103634)

  • 1. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
    Myers R; Harvey M; Kaufmann TJ; Greiner SM; Krempski JW; Raffel C; Shelton SE; Soeffker D; Zollman P; Federspiel MJ; Blanco M; Galanis E
    Hum Gene Ther; 2008 Jul; 19(7):690-8. PubMed ID: 18576918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
    Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
    Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
    Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
    Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
    McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
    Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
    Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ
    Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
    Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
    Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
    Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
    BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
    Msaouel P; Dispenzieri A; Galanis E
    Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
    Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
    Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
    Galanis E; Dooley KE; Keith Anderson S; Kurokawa CB; Carrero XW; Uhm JH; Federspiel MJ; Leontovich AA; Aderca I; Viker KB; Hammack JE; Marks RS; Robinson SI; Johnson DR; Kaufmann TJ; Buckner JC; Lachance DH; Burns TC; Giannini C; Raghunathan A; Iankov ID; Parney IF
    Nat Commun; 2024 Jan; 15(1):493. PubMed ID: 38216554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
    Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
    BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.